Home › Ovarian Cancer › NCT07690189

Study of NTB-928 in R/R OC

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Expansion Study of NTB-928, a FRα-Targeting Bispecific T Cell Engager, in Subjects With Relapsed/Refractory Ovarian Carcinoma

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Aged 18 years or older
* Have a confirmed diagnosis of ovarian cancer, including high-grade serous, high-grade endometrioid, low-grade serous, or clear cell ovarian cancer, or carcinosarcoma of the ovary. Patients with mucinous carcinoma are not eligible.
* Have relapsed or refractory ovarian cancer and have already received standard treatments known to provide benefit; participants are eligible if they have platinum-refractory, platinum-resistant, or platinum-sensitive ovarian cancer (with clearly documented ineligibility for further platinum chemotherapy).
* Are able to understand the study requirements and are willing to provide written informed consent
* Are willing to use effective birth control during the study and for a period after the last dose of study treatment, if of childbearing potential

Exclusion Criteria:

* Have another active cancer that could interfere with assessment of this study treatment
* Have received another investigational drug or certain cancer treatments within a recent period before starting this study
* Are pregnant or breastfeeding

About the study

The goal of this clinical trial is to determine if NTB-928 can be given safely to adult females with ovarian cancer that has come back (relapsed) or stopped responding to treatment (refractory), how NTB-928 moves through the body, and how the immune system reacts to it. The study will also look for early signs of anti-cancer activity of NTB-928. The main questions the study aims to answer are:

* What side effects do participants experience when receiving NTB-928, including side effects that limit how much of it can be safely given? * How is NTB-928 processed by the body at different dose levels? * Does the immune system react to NTB-928 during treatment? * What dose of NTB-928 can be given safely that shows early signs of activity against ovarian cancer?

What is being tested

• NTB-928 (drug)

Sponsor: TeneoSeven, Inc. · Participants: 90 · Started: Jun 29, 2026

Contact the study team

• Clinical Trial Information · Phone: 510-392-0929

Official record on ClinicalTrials.gov — NCT07690189

Locations in the U.S.

Conditions

• Ovarian Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.